Unicycive Therapeutics Stock Fundamentals
| UNCY Stock | USD 0.54 0.03 4.91% |
Unicycive Therapeutics fundamentals help investors to digest information that contributes to Unicycive Therapeutics' financial success or failures. It also enables traders to predict the movement of Unicycive Stock. The fundamental analysis module provides a way to measure Unicycive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unicycive Therapeutics stock.
At this time, Unicycive Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 386.4 K in 2025, whereas Interest Expense is likely to drop slightly above 89.6 K in 2025. Unicycive | Select Account or Indicator |
Unicycive Therapeutics Company Return On Equity Analysis
Unicycive Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Unicycive Therapeutics Return On Equity | -1.47 |
Most of Unicycive Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Unicycive Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Unicycive Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Unicycive Therapeutics has a Return On Equity of -1.4705. This is 93.87% lower than that of the Biotechnology sector and 95.97% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Unicycive Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Unicycive Therapeutics's current stock value. Our valuation model uses many indicators to compare Unicycive Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Unicycive Therapeutics competition to find correlations between indicators driving Unicycive Therapeutics's intrinsic value. More Info.Unicycive Therapeutics is rated third in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Unicycive Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Unicycive Therapeutics' earnings, one of the primary drivers of an investment's value.Unicycive Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Unicycive Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Unicycive Therapeutics could also be used in its relative valuation, which is a method of valuing Unicycive Therapeutics by comparing valuation metrics of similar companies.Unicycive Therapeutics is currently under evaluation in return on equity category among its peers.
Unicycive Fundamentals
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 27.74 M | ||||
| Shares Outstanding | 103.8 M | ||||
| Shares Owned By Insiders | 6.12 % | ||||
| Shares Owned By Institutions | 70.48 % | ||||
| Number Of Shares Shorted | 823.32 K | ||||
| Price To Book | 2.30 X | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K | ||||
| EBITDA | (30.18 M) | ||||
| Net Income | (30.54 M) | ||||
| Cash And Equivalents | 10.57 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 811 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.43 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (18.28 M) | ||||
| Short Ratio | 0.72 X | ||||
| Earnings Per Share | (0.46) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.23 | ||||
| Market Capitalization | 59.16 M | ||||
| Total Asset | 14.19 M | ||||
| Retained Earnings | (64.54 M) | ||||
| Working Capital | (4.13 M) | ||||
| Net Asset | 14.19 M |
About Unicycive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Unicycive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -16.2 K | -17 K | |
| Total Revenue | 776.2 K | 815.1 K | |
| Cost Of Revenue | 326.6 K | 342.9 K | |
| Stock Based Compensation To Revenue | 2.36 | 1.49 | |
| Sales General And Administrative To Revenue | 11.40 | 7.82 | |
| Research And Ddevelopement To Revenue | 17.20 | 12.88 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 0.03 | 0.05 | |
| Ebit Per Revenue | (35.39) | (37.16) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.